Eupraxia Pharmaceuticals Inc.
Support and Resistance Levels
Past performance
News About EPRX
All events for EPRX
All deals for EPRX
Financial Ratios
Financial Statements
EPRX vs Sector & Peers
About Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Website eupraxiapharma.com
Headquarters Victoria, BC, CA